re: staying steady Hello, once again.
Lets do some maths... lets just say that 100 surgeons attend this annual conference (just say, mind you) and just 25 of them decide to "go" with the device. Now lets say that they will each perform one implant per month for the first year to private patients (cashies - not love-jobs). Now add to this the US trials for BTT and DT (another 190 +/- units) then you have passed the 450 mark. and this is only in the first year. One important variable would be that the trial in the US wont be completed in the 12 months....
Say the revenue per unit to the company is $100k and costs are in the vecinity of 60% then you would be looking at a gross margin of profit around $19.6m
(25x12=300, plus 190, = 490. x $100,000 = $49m - 60% costs, = $19.6m)
So, there you have it, based on just 25 surgeons taking this device onboard. One would safely say that it would be widely accepted by the Cardiothoracic community (of suregons), going by the results to date of over 60 implants - one already having received a donor heart transplant. And not to mention the broad age range of recipients and their (now) new lifestyle...all positives
I'm assuming that the production facility in Sydney can be ramped-up to go to two or three shifts, instead of the current one shift, but with a device such as this, one wouldn't want to compromise quality assurance in production by placing huge demands on staff... No doubt, there would already be a stock-pile of product, but the plant in Kirawee in Sydney would have to be enlarged again to handle anything like the demand mentioned in Ventracors annual report of a couple of years ago... 800k in America alone per year suffering with end-stage congestive heart failure. Add to this figure Europe, Asia and then divide it by all the other up and coming companies, and there is still a huge market... its just the Money....where is it going to come from? How many "Fred and Freda Factory's" can afford to pay for the op?
I Hold (passionately)
VCR
ventracor limited
